The effect of radiation quality on the risks of second malignancies

References

• Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE, et al. 2003. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Belli M, Cherubini R, Finotto S, Moschini G, Sapora O, Simone G, Tabocchini MA. 1989. RBE-LET relationship for the survival of V79 cells irradiated with low energy protons. Int J Radiat Biol 55:93–104.
   PubMed Web of Science ®Google Scholar
• Belli M, Goodhead DT, Ianzini F, Simone G, Tabocchini MA, et al. 1992. Direct comparison of biological effectiveness of protons and alpha-particles of the same LET. II. Mutation induction at the HPRT locus in V79 cells. Int J Radiat Biol 61:625–629.
   PubMed Web of Science ®Google Scholar
• Belli M, Cera F, Cherubini R, Dalla Vecchia M, Haque AM, Ianzini F, Moschini G, et al. 1998. RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: Further results at the LNL facility. Int J Radiat Biol 74:501–509.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. 2008. Secondary neutrons in clinical proton radiotherapy: A charged issue. Radiother Oncol 86:165–170.
   PubMed Web of Science ®Google Scholar
• Chen DJ, Tsuboi K, Nguyen T, Yang CT. 1994. Charged-particle mutagenesis II. Mutagenic effects of high energy charged particles in human fibroblasts. Advances Space Res 14:347–354.
   PubMedGoogle Scholar
• Chen Y, Ahmad S. 2012. Empirical model estimation of relative biological effectiveness for proton beam therapy. Radiat Protect Dosimetry 149:116–123.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I, Olofsson J, Karlsson M. 2005. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncologica 44:339–347.
   PubMed Web of Science ®Google Scholar
• Folkard M, Prise KM, Vojnovic B, Davies S, Roper MJ, Michael BD. 1989. The irradiation of V79 mammalian cells by protons with energies below 2 MeV. I: Experimental arrangement and measurements of cell survival. Int J Radiat Biol 56:221–237.
   PubMed Web of Science ®Google Scholar
• Furusawa Y, Fukutsu K, Aoki M, Itsukaichi H, Eguchi-Kasai K, Ohara H, Yatagai F, et al. 2000. Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated (3)He-, (12)C- and (20)Ne-ion beams. Radiat Res 154:485–496.
   PubMed Web of Science ®Google Scholar
• Goodhead DT, Belli M, Mill AJ, Bance DA, Allen LA, Hall SC, Ianzani F, et al. 1992. Direct comparison between protons and alpha-particles of the same LET: I. Irradiation methods and inactivation of asynchronous V79, HeLa and C3H 10T1/2 cells. Int J Radiat Biol 61:611–624.
   PubMed Web of Science ®Google Scholar
• Gilbert E, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, et al. 2003. Lung cancer after treatment for Hodgkin's disease: Focus on radiation effects. Radiat Res 159:161–173.
   PubMed Web of Science ®Google Scholar
• Hei TK, Chen DJ, Brenner DJ, Hall EJ. 1988. Mutation induction by charged particles of defined linear energy transfer. Carcinogenesis 9:1233–1236.
   PubMed Web of Science ®Google Scholar
• Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, et al. 2005. Breast cancer risk following radiotherapy for Hodgkin lymphoma: Modification by other risk factors. Blood 106:3358–3365.
   PubMed Web of Science ®Google Scholar
• Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, et al. 2007a. Long-term solid cancer risk among five-year survivors of Hodgkin's lymphoma. J Clin Oncol 25: 1489–1497.
   PubMed Web of Science ®Google Scholar
• Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, Xu T, Huang L, Sachs RK, Brenner DJ. 2007b. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586.
   PubMed Web of Science ®Google Scholar
• Lindsay KA, Wheldon EG, Deehan C, Wheldon TE. 2001. Radiation carcinogenesis modelling for risk of treatment-related second tumors following radiotherapy. Br J Radiol 74:529–536.
   PubMed Web of Science ®Google Scholar
• Newhauser WD, Durante M. 2011. Assessing the risk of second malignancies after modern radiotherapy. Nature Rev Cancer 11: 438–448.
   PubMed Web of Science ®Google Scholar
• Paganetti H. 2012. Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy. Health Phys 103:652–661.
   PubMed Web of Science ®Google Scholar
• Sachs RK, Brenner DJ. 2005. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 102:13040–13045.
   PubMed Web of Science ®Google Scholar
• Schneider U, Lomax A, Lombriser N. 2000. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation. Radiat Res 154:382–388.
   PubMed Web of Science ®Google Scholar
• Shuryak I, Hahnfeldt P, Hlatky L, Sachs RK and Brenner DJ. 2009a. A new view of radiation-induced cancer: Integrating short- and long-term processes. Part I: Approach. Radiat Environ Biophys 48:263–274.
   PubMed Web of Science ®Google Scholar
• Shuryak I, Hahnfeldt P, Hlatky L, Sachs RK, Brenner DJ. 2009b. A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: Second cancer risk estimation. Radiat Environ Biophys 48:275–286.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, et al. 2000. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18:498–509.
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, et al. 2005. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428–1437.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, Crommelin MA, et al. 2003. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95:971–980.
   PubMed Web of Science ®Google Scholar
• Wenzl T, Wilkens JJ. 2011. Modelling of the oxygen enhancement ratio for ion beam radiation therapy. Phys Med Biol 56:3251–3268.
   PubMed Web of Science ®Google Scholar
• Wilkens JJ, Oelfke U. 2003. Analytical linear energy transfer calculations for proton therapy. Med Phys 30:806–815.
   PubMed Web of Science ®Google Scholar
• Wilkens JJ, Oelfke U. 2004. A phenomenological model for the relative biological effectiveness in therapeutic proton beams. Phys Med Biol 49:2811–2825.
   PubMed Web of Science ®Google Scholar
• Xu XG, Bednarz B, Paganetti H. 2008. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 53:R193–241.
   Web of Science ®Google Scholar
• Yatagai F. 2004. Mutations induced by heavy charged particles. Biolog Sci Space 18:224–234.
   PubMedGoogle Scholar
• Zacharatou Jarlskog C, Paganetti H. 2008. Risk of developing second cancer from neutron dose in proton therapy function of field characteristics, organ, and patient age. Int J Radiat Oncol Biol Phys 72:228–235.
   PubMed Web of Science ®Google Scholar